Farnesyltransferase inhibition in HGPS.
Cell
; 184(2): 293, 2021 01 21.
Article
em En
| MEDLINE
| ID: mdl-33482093
ABSTRACT
The ultra-rare, pediatric premature aging disorder Hutchinson-Gilford progeria syndrome (HGPS) is caused by mutation of LMNA, encoding the nuclear architectural protein lamin A. Patients develop atherosclerosis and typically die of heart failure in their teens. FDA-approved Zokinvy prevents farnesylation of lamin A, reduces vascular stiffness, and extends survival in HGPS patients. To view this Bench to Bedside, open or download the PDF.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Progéria
/
Inibidores Enzimáticos
/
Farnesiltranstransferase
Limite:
Humans
Idioma:
En
Ano de publicação:
2021
Tipo de documento:
Article